Clinical Features of Primary Vitreoretinal Lymphoma: A Single-center Study.
Clinical Features of Primary Vitreoretinal Lymphoma: A Single-center Study.
复制标题
DOI：
10.21873/cdp.10010
复制
发表时间：
2021-05-01
期刊：
影响因子：
--
通讯作者：
Ishida, Susumu
中科院分区：
文献类型：
--
作者：
Kase, Satoru;Namba, Kenichi;Ishida, Susumu
背景/目的：本研究旨在探讨原发性玻璃体视网膜淋巴瘤（PVRL）的临床预后。患者和方法：17例曾在北海道大学医院接受治疗的PVRL患者入组研究。根据细胞学、白细胞介素-10/-6比值和免疫球蛋白重链（IgH）基因重排进行诊断。结果：细胞恶性肿瘤14例（82.3%），白细胞介素-10/-6高比值16例（94.1%），IgH单克隆13例（76.5%）。7例（41.2%）患者在诊断为PVRL前接受了全身皮质类固醇治疗。诊断后的治疗分别为玻璃体内注射甲氨蝶呤、局部放疗和静脉化疗，分别为11例、7例和5例。中枢神经系统和全身受累分别为9例和1例，这些并发症发生在首次眼部表现后3至43个月（平均=16个月）。结论：我们的许多患者没有接受任何系统干预，几乎一半的PVRL患者在随访期间出现中枢神经系统受累。
Background/Aim: This study aimed to demonstrate the clinical outcomes of primary vitreoretinal lymphoma (PVRL).Patients and Methods: Seventeen patients with PVRL who had been treated at Hokkaido University Hospital were enrolled in this study. They were diagnosed based on their cytology, interleukin-10/-6 ratio, and immunoglobulin heavy chain (IgH) gene rearrangement.Results: Diagnostic tests detected cytological malignancy among 14 cases (82.3%), high interleukin-10/-6 ratios among 16 cases (94.1%), and IgH monoclonality in 13 cases (76.5%). Systemic corticosteroids were given to seven (41.2%) patients before their diagnosis of PVRL. Treatments after diagnosis comprised intravitreal methotrexate injection, local radiation, and intravenous chemotherapy for 11, seven, and five cases, respectively. Central nervous system and systemic involvements were observed in nine and one case, respectively, and these complications occurred at 3 to 43 months (mean=16 months) after initial ocular presentation.Conclusion: Many of our patients did not receive any systemic intervention, and almost half of patients with PVRL developed central nervous system involvement during their follow-up period.